Table II.
Association between CFS-NLR and the clinicopathological characteristics of patients with gastric cancer.
| CFS-NLR group, n (%) | ||||
|---|---|---|---|---|
| Characteristics | Group 0 | Group 1 | Group 2 | P-value |
| Total | 80 (100.0) | 130 (100.0) | 65 (100.0) | |
| Gender | 0.1960 | |||
| Male | 52 (65.0) | 79 (60.8) | 48 (73.9) | |
| Female | 28 (35.0) | 51 (39.2) | 17 (26.1) | |
| Age, years | 0.5540 | |||
| ≤70 | 50 (62.5) | 74 (56.9) | 35 (53.8) | |
| >70 | 30 (37.5) | 56 (43.1) | 30 (46.2) | |
| Tumor location | 0.0720 | |||
| Upper | 21 (26.2) | 26 (20.0) | 23 (35.4) | |
| Middle | 35 (43.8) | 61 (46.9) | 18 (27.7) | |
| Lower | 24 (30.0) | 43 (33.1) | 24 (36.9) | |
| Histological type | 0.0730 | |||
| Differentiated | 36 (45.0) | 55 (42.3) | 18 (27.7) | |
| Undifferentiated | 44 (55.0) | 75 (57.7) | 47 (72.3) | |
| Depth of tumor invasion | <0.0001 | |||
| pT1-T2 | 64 (80.0) | 75 (57.7) | 16 (24.6) | |
| pT3-T4 | 16 (20.0) | 55 (42.3) | 49 (75.4) | |
| Lymph node metastasis | <0.0001 | |||
| Negative | 55 (68.8) | 71 (54.6) | 19 (29.2) | |
| Positive | 25 (31.2) | 59 (45.4) | 46 (70.8) | |
| Lymphatic invasion | <0.0001 | |||
| Negative | 53 (66.3) | 60 (46.2) | 20 (30.8) | |
| Positive | 27 (33.7) | 70 (53.8) | 45 (69.2) | |
| Venous invasion | <0.0001 | |||
| Negative | 59 (73.8) | 73 (56.2) | 20 (30.8) | |
| Positive | 21 (26.2) | 57 (43.8) | 45 (69.2) | |
| Tumor stage | <0.0001 | |||
| I–II | 69 (86.3) | 91 (70.0) | 23 (35.4) | |
| III–IV | 11 (13.7) | 39 (30.0) | 42 (64.6) | |
CFS-NLR, combined fibrinogen concentration and neutrophil-lymphocyte ratio; pT1, invasion of lamina propria or submucosa; pT2, invasion of muscularis propria; pT3, invasion of subserosa; pT4, penetration of serosa or invasion of adjacent structures.